scholarly journals Single-Chain Bifunctional Vascular Endothelial Growth Factor (VEGF)-Follicle-Stimulating Hormone (FSH)-C-Terminal Peptide (CTP) Is Superior to the Combination Therapy of Recombinant VEGF plus FSH-CTP in Stimulating Angiogenesis during Ovarian Folliculogenesis

Endocrinology ◽  
2007 ◽  
Vol 148 (3) ◽  
pp. 1296-1305 ◽  
Author(s):  
Rhonda K. Trousdale ◽  
Susan V. Pollak ◽  
Jeffrey Klein ◽  
Leslie Lobel ◽  
Yasuhiro Funahashi ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Combination Therapy ◽  
Follicle Stimulating Hormone ◽  
Vascular Endothelial ◽  
Single Chain ◽  
Ovarian Folliculogenesis ◽  
Endothelial Growth Factor ◽  
Stimulating Hormone

scholarly journals Photodynamic therapy combined with anti-vascular endothelial growth factor therapy for pachychoroid neovasculopathy

PLoS ONE ◽  
2021 ◽  
Vol 16 (3) ◽  
pp. e0248760
Author(s):  
Akiko Miki ◽  
Sentaro Kusuhara ◽  
Tsuyoshi Otsuji ◽  
Yu Kawashima ◽  
Katsuaki Miki ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Photodynamic Therapy ◽  
Growth Factor ◽  
Combination Therapy ◽  
Vascular Endothelial ◽  
Anti Vegf ◽  
Initial Combination Therapy ◽  
Pachychoroid Neovasculopathy ◽  
Endothelial Growth Factor ◽  
Initial Combination

This multicenter retrospective study was conducted to evaluate the 1-year treatment outcome of photodynamic therapy (PDT) combined with anti-vascular endothelial growth factor (VEGF) therapy for pachychoroid neovasculopathy (PNV). A total of 42 eyes of 42 patients with treatment-naïve PNV who were treated with PDT combined with intravitreal injections of an anti-VEGF agent (ranibizumab or aflibercept) for 1 year. All eyes showed exudative and/or hemorrhagic changes that affected the fovea at baseline. After the initial combination therapy, subfoveal choroidal thickness (SCT) and central retinal thickness (CRT) were significantly reduced and were maintained as such for 12 months (P < 0.01 in SCT and CRT). The best-corrected visual acuity (BCVA) (0.19 ± 0.30 at baseline) significantly improved at 3 months (0.15 ± 0.29, P < 0.05) and further improved at 12 months (0.10 ± 0.30, P < 0.01) when compared to that at baseline. After the initial combination therapy, 32 eyes (76.2%) required no additional treatments for 12 months. The mean number of additional PDT and intravitreal injections of anti-VEGF agents was 0.1 ± 0.3 and 0.9 ± 1.9, respectively. Of the 42 eyes included in this study, 22 eyes (52.4%) had polypoidal lesions at baseline. No significant differences in SCT, CRT, or BCVA were observed at any time points between eyes with and without polypoidal lesions. Of 20 eyes without polypoidal lesions, only 1 eye (5.0%) needed additional treatments. PNV, especially without polypoidal lesions, can be treated effectively with PDT combined with anti-VEGF therapy with few sessions.

scholarly journals Affinity-Enhanced Multimeric VEGF (Vascular Endothelial Growth Factor) and PlGF (Placental Growth Factor) Variants for Specific Adsorption of sFlt-1 to Restore Angiogenic Balance in Preeclampsia

Hypertension ◽  
2020 ◽  
Vol 76 (4) ◽  
pp. 1176-1184 ◽  
Author(s):  
Mahsa Matin ◽  
Matthias Mörgelin ◽  
Jörg Stetefeld ◽  
Bernhard Schermer ◽  
Paul T. Brinkkoetter ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Ex Vivo ◽  
Placental Growth Factor ◽  
Vascular Endothelial ◽  
Single Chain ◽  
Serum Samples ◽  
Multisystem Disease ◽  
Angiogenic Balance ◽  
Endothelial Growth Factor

Preeclampsia is a potentially life-threatening multisystem disease affecting 4% to 8% of pregnant women after the 20th week of gestation. An excess of placental expressed antiangiogenic soluble VEGF (vascular endothelial growth factor)-receptor 1 (soluble FMS-like tyrosine kinase 1) scavenges VEGF and PlGF (placental growth factor), causing generalized endothelial dysfunction. Interventions to restore the angiogenic balance in preeclamptic pregnancies are intensively studied and improve maternal and neonatal outcomes. Especially extracorporeal strategies to remove sFlt-1 are promising in human pregnancy. However, available apheresis systems adsorb sFlt-1 unspecifically and with low efficiency. Affinity-enhanced ligands are needed to improve performance and compatibility of apheresis treatments. Using computerized molecular modeling, we developed multimeric VEGF molecules comprised of single-chain VEGF 165 dimers (scVEGF 165 ). A short peptide linker hampers intrachain dimerization to induce assembly preferably as tetrameric molecules as visualized in negative staining electron microscopy. scVEGF 165 multimers possess 1.2-fold higher affinity for sFlt-1 as compared to the available antibodies or monomeric VEGF. Consequently, scVEGF multimers have the ability to competitively release sFlt-1 bound PlGF and, in particular, VEGF. In ex vivo adsorption experiments using serum samples from patients with preeclampsia, scVEGF multimers reduce sFlt-1 levels by 85% and increase PlGF and VEGF levels by 20- and 9-fold, respectively. Finally, performance and stability of sFlt-1 capturing scVEGF 165 multimers were scrutinized on different matrices of which biocompatible agarose matrix yielded optimal results. We introduce the first VEGF-based highly efficient sFlt-1 apheresis system that is directly applicable in vivo due to utilization of inert agarose matrix, using a homomultimeric form of VEGF 165 to restore the angiogenic balance in preeclampsia.

Sign in / Sign up

Export Citation Format

Share Document